Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, Maryland.
JAMA Surg. 2019 Dec 1;154(12):1103-1109. doi: 10.1001/jamasurg.2019.2845.
Among liver transplant candidates, obesity and frailty are associated with increased risk of death while they are on the wait-list. However, use of body mass index (BMI) may not detect candidates at a higher risk of death owing to the fact that ascites and muscle wasting are seen across transplant candidates of all BMI measurements.
To evaluate whether the association between wait-list mortality and frailty varied by BMI of liver transplant candidates.
DESIGN, SETTING, AND PARTICIPANTS: A prospective cohort study was conducted at 9 liver transplant centers in the United States from March 1, 2012, to May 1, 2018, among 1108 adult liver transplant candidates without hepatocellular carcinoma.
At outpatient evaluation, the Liver Frailty Index score was calculated (grip strength, chair stands, and balance), with frailty defined as a Liver Frailty Index score of 4.5 or more. Candidates' BMI was categorized as nonobese (18.5-29.9), class 1 obesity (30.0-34.9), and class 2 or greater obesity (≥35.0).
The risk of wait-list mortality was quantified using competing risks regression by candidate frailty, adjusting for age, sex, race/ethnicity, Model for End-stage Liver Disease Sodium score, cause of liver disease, and ascites, including an interaction with candidate BMI.
Of 1108 liver transplant candidates (474 women and 634 men; mean [SD] age, 55 [10] years), 290 (26.2%) were frail; 170 of 670 nonobese candidates (25.4%), 64 of 246 candidates with class 1 obesity (26.0%), and 56 of 192 candidates with class 2 or greater obesity (29.2%) were frail (P = .57). Frail nonobese candidates and frail candidates with class 1 obesity had a higher risk of wait-list mortality compared with their nonfrail counterparts (nonobese candidates: adjusted subhazard ratio, 1.54; 95% CI, 1.02-2.33; P = .04; and candidates with class 1 obesity: adjusted subhazard ratio, 1.72; 95% CI, 0.99-2.99; P = .06; P = .75 for interaction). However, frail candidates with class 2 or greater obesity had a 3.19-fold higher adjusted risk of wait-list mortality compared with nonfrail candidates with class 2 or greater obesity (95% CI, 1.75-5.82; P < .001; P = .047 for interaction).
This study's finding suggest that among nonobese liver transplant candidates and candidates with class 1 obesity, frailty was associated with a 2-fold higher risk of wait-list mortality. However, the mortality risk associated with frailty differed for candidates with class 2 or greater obesity, with frail candidates having a more than 3-fold higher risk of wait-list mortality compared with nonfrail patients. Frailty assessments may help to identify vulnerable patients, particularly those with a BMI of 35.0 or more, in whom a clinician's visual evaluation may be less reliable to assess muscle mass and nutritional status.
在肝移植候选者中,肥胖和虚弱与等待名单上的死亡风险增加有关。然而,由于腹水和肌肉消耗在所有 BMI 测量的移植候选者中都可见,使用体重指数 (BMI) 可能无法检测到死亡风险较高的患者。
评估肝移植候选者的等待名单死亡率与虚弱之间的关联是否因 BMI 而异。
设计、地点和参与者:这是一项在美国 9 家肝脏移植中心进行的前瞻性队列研究,时间为 2012 年 3 月 1 日至 2018 年 5 月 1 日,研究对象为 1108 名无肝细胞癌的成年肝移植候选者。
在门诊评估时,计算了肝虚弱指数评分(握力、椅子站立和平衡),将虚弱定义为肝虚弱指数评分达到 4.5 或更高。候选者的 BMI 分为非肥胖(18.5-29.9)、1 类肥胖(30.0-34.9)和 2 类或更高肥胖(≥35.0)。
使用竞争风险回归量化等待名单死亡率,调整候选者的年龄、性别、种族/民族、终末期肝病钠评分、肝病病因和腹水,包括与候选者 BMI 的交互作用。
在 1108 名肝移植候选者中(474 名女性和 634 名男性;平均[标准差]年龄为 55[10]岁),290 名(26.2%)为虚弱;670 名非肥胖候选者中有 170 名(25.4%),246 名 1 类肥胖候选者中有 64 名(26.0%),192 名 2 类或更高肥胖候选者中有 56 名(29.2%)为虚弱(P = .57)。非肥胖虚弱候选者和 1 类肥胖虚弱候选者与非虚弱对照者相比,等待名单死亡率更高(非肥胖候选者:调整后的亚危险比,1.54;95%CI,1.02-2.33;P = .04;1 类肥胖候选者:调整后的亚危险比,1.72;95%CI,0.99-2.99;P = .06;P = .75 用于交互作用)。然而,2 类或更高肥胖的虚弱候选者与 2 类或更高肥胖的非虚弱候选者相比,等待名单死亡率高出 3.19 倍(95%CI,1.75-5.82;P < .001;P = .047 用于交互作用)。
这项研究的发现表明,在非肥胖的肝移植候选者和 1 类肥胖的候选者中,虚弱与等待名单上的死亡风险增加 2 倍有关。然而,对于 BMI 为 35.0 或更高的候选者,虚弱与死亡率相关的风险不同,虚弱候选者的等待名单死亡率比非虚弱患者高出 3 倍以上。虚弱评估可能有助于识别脆弱患者,特别是那些 BMI 为 35.0 或更高的患者,因为临床医生的视觉评估可能不太可靠,无法评估肌肉质量和营养状况。